The biotechnology firm is currently evaluating a one-time, in-office gene therapy designed to address diabetic retinopathy, a condition linked to diabetes that frequently results in vision loss. The study aims to determine if the treatment improves disease severity by at least two steps on the standard clinical scale over a one-year period. This development continues a strong rally for the company, which has seen its share price increase by more than 50% over the last three months. The Phase IIb portion of the trial is projected to enroll approximately 135 participants across the United States.